News | September 10, 2025
Sirio secures TGA GMP certification to support strategic growth in Australia
The Ma’anshan site approval covers pastilles, oral liquids, and powders
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
This project shall be implemented through incorporation of a new joint venture company in Zambia
The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Subscribe To Our Newsletter & Stay Updated
